Bird Flu > Bird Flu News > Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.